{"id":355941,"date":"2026-11-19T16:06:05","date_gmt":"2026-11-19T10:36:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355941"},"modified":"2026-11-19T16:06:05","modified_gmt":"2026-11-19T10:36:05","slug":"heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/","title":{"rendered":"3 Heart Care Medicines Brand, Bank Technology Provider and Namkeen Snacks Maker Stocks With a Strong Future Roadmap: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International: ROE of 15.9% to 33.7% and FY22 to FY26 revenue CAGR of 10.4% to 22.9%. Prices as of 18 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>cardiac drug, bank software and namkeen stocks<\/strong> to watch are <strong>Eris Lifesciences<\/strong>, <strong>Oracle Financial Services Software<\/strong> and <strong>Bikaji Foods International<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>15.9% to 33.7%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 10.4% to 22.9%. Oracle Financial Services Software has the highest return on equity at 33.7%, while Eris Lifesciences has the fastest revenue growth at 22.9% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Cardiac drug, bank software and namkeen stocks offer a focused view of a sector where demand keeps widening. Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International cover a branded medicines company, a banking software company and an ethnic snacks maker.<\/p>\n<p>This list covers three cardiac drug, bank software and namkeen stocks with complete current figures: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#What_Are_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"What Are Cardiac Drug, Bank Software and Namkeen Stocks?\">What Are Cardiac Drug, Bank Software and Namkeen Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Cardiac_Drug_Bank_Software_and_Namkeen_Stocks_at_a_Glance\" title=\"Cardiac Drug, Bank Software and Namkeen Stocks at a Glance\">Cardiac Drug, Bank Software and Namkeen Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Why_Do_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Cardiac Drug, Bank Software and Namkeen Stocks Have a Strong Roadmap in India?\">Why Do Cardiac Drug, Bank Software and Namkeen Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Why_Eris_Lifesciences_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"Why Eris Lifesciences Features Among These Cardiac Drug, Bank Software and Namkeen Stocks\">Why Eris Lifesciences Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Why_Oracle_Financial_Services_Software_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"Why Oracle Financial Services Software Features Among These Cardiac Drug, Bank Software and Namkeen Stocks\">Why Oracle Financial Services Software Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Why_Bikaji_Foods_International_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"Why Bikaji Foods International Features Among These Cardiac Drug, Bank Software and Namkeen Stocks\">Why Bikaji Foods International Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Eris_Lifesciences_vs_Oracle_Financial_Services_Software_vs_Bikaji_Foods_International_on_Key_Financials\" title=\"Eris Lifesciences vs Oracle Financial Services Software vs Bikaji Foods International on Key Financials\">Eris Lifesciences vs Oracle Financial Services Software vs Bikaji Foods International on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Key_Risks_to_Check_Before_Investing_in_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"Key Risks to Check Before Investing in Cardiac Drug, Bank Software and Namkeen Stocks\">Key Risks to Check Before Investing in Cardiac Drug, Bank Software and Namkeen Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Final_Thoughts_on_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\" title=\"Final Thoughts on Cardiac Drug, Bank Software and Namkeen Stocks\">Final Thoughts on Cardiac Drug, Bank Software and Namkeen Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#What_are_cardiac_drug_bank_software_and_namkeen_stocks\" title=\"What are cardiac drug, bank software and namkeen stocks?\">What are cardiac drug, bank software and namkeen stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Which_cardiac_drug_bank_software_and_namkeen_stocks_are_covered_in_this_list\" title=\"Which cardiac drug, bank software and namkeen stocks are covered in this list?\">Which cardiac drug, bank software and namkeen stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Why_do_cardiac_drug_bank_software_and_namkeen_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do cardiac drug, bank software and namkeen stocks have a strong future roadmap in India?\">Why do cardiac drug, bank software and namkeen stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#How_has_Eris_Lifesciences_performed_financially\" title=\"How has Eris Lifesciences performed financially?\">How has Eris Lifesciences performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#How_has_Oracle_Financial_Services_Software_performed_financially\" title=\"How has Oracle Financial Services Software performed financially?\">How has Oracle Financial Services Software performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#How_has_Bikaji_Foods_International_performed_financially\" title=\"How has Bikaji Foods International performed financially?\">How has Bikaji Foods International performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#What_risks_should_investors_check_before_buying_cardiac_drug_bank_software_and_namkeen_stocks\" title=\"What risks should investors check before buying cardiac drug, bank software and namkeen stocks?\">What risks should investors check before buying cardiac drug, bank software and namkeen stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker-stocks-roadmap-badland-list\/#Is_this_list_of_cardiac_drug_bank_software_and_namkeen_stocks_investment_advice\" title=\"Is this list of cardiac drug, bank software and namkeen stocks investment advice?\">Is this list of cardiac drug, bank software and namkeen stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>What Are Cardiac Drug, Bank Software and Namkeen Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cardiac drug, bank software and namkeen stocks<\/strong> are listed companies that sell branded medicines for heart and diabetes care, build software that banks use for daily operations, and make bhujia, namkeen and sweets sold across India. Their earnings depend on medicine demand, bank technology budgets and snack demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cardiac_Drug_Bank_Software_and_Namkeen_Stocks_at_a_Glance\"><\/span><strong>Cardiac Drug, Bank Software and Namkeen Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/eris\/eris-lifesciences-ltd-share-price-today\">Eris Lifesciences<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,337.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.60<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ofss\/oracle-financial-services-software-ltd-share-price-today\">Oracle Financial Services Software<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,694.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">86,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/bikaji\/bikaji-foods-international-ltd-share-price-today\">Bikaji Foods International<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">480.75<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,686<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.19<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Eris Lifesciences trades at a <strong>P\/E<\/strong> below the industry P\/E, while Oracle Financial Services Software and Bikaji Foods International trade above it, which reflects the growth the market already expects. Readers comparing cardiac drug, bank software and namkeen stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cardiac drug, bank software and namkeen stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Cardiac Drug, Bank Software and Namkeen Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cardiac drug, bank software and namkeen stocks<\/strong> have a strong roadmap in India because steady demand for chronic care medicines, banks upgrading their systems and rising demand for packaged snacks keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Branded medicines.<\/strong> Patients stay on long-term treatment.<\/li>\n<li><strong>Banking software.<\/strong> Banks upgrade their core systems.<\/li>\n<li><strong>Snacks.<\/strong> Households buy packaged namkeen.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Eris_Lifesciences_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>Why Eris Lifesciences Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the cardiac drug, bank software and namkeen stocks on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.<\/p>\n<p>The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a <strong>market capitalisation<\/strong> of Rs 15,618 crore. The stock trades at a <strong>P\/E<\/strong> of 23.5, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<p><strong>What to watch:<\/strong> Check how smoothly acquired brands are integrated and how the injectables unit scales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Oracle_Financial_Services_Software_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>Why Oracle Financial Services Software Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the chronic care medicines, bank technology and snacks shares on this list, Oracle Financial Services Software develops banking software products such as core banking, lending and risk platforms and also provides related services and support to banks and financial institutions around the world.<\/p>\n<p>Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%.<\/p>\n<p>The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P\/E of 25.2, above the industry P\/E of 17.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.<\/p>\n<p><strong>What to watch:<\/strong> Follow product licence wins, cloud adoption by banking clients and the pace of new deals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Bikaji_Foods_International_Features_Among_These_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>Why Bikaji Foods International Features Among These Cardiac Drug, Bank Software and Namkeen Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Bikaji Foods International, headquartered in Bikaner, makes traditional Indian snacks such as bhujia and namkeen, along with sweets, papad and other packaged foods.<\/p>\n<p>In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%.<\/p>\n<p>Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 45.8, above the industry P\/E of 33.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.<\/p>\n<p><strong>What to watch:<\/strong> Track distribution expansion and input costs for edible oils and potatoes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Eris_Lifesciences_vs_Oracle_Financial_Services_Software_vs_Bikaji_Foods_International_on_Key_Financials\"><\/span><strong>Eris Lifesciences vs Oracle Financial Services Software vs Bikaji Foods International on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three cardiac drug, bank software and namkeen stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Eris Lifesciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,373<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,137<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">648<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Oracle Financial Services Software<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,943<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,639<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Bikaji Foods International<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,621<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,045<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">254<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Oracle Financial Services Software posts the highest return on equity in this group at 33.7%. Oracle Financial Services Software has the largest FY26 revenue at Rs 7,943 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with <strong>cardiac drug, bank software and namkeen stocks<\/strong> is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Cardiac Drug, Bank Software and Namkeen Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these cardiac drug, bank software and namkeen stocks, the main points are: Long-term chronic care medicines, bank technology and snacks shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Raw material costs.<\/strong> Ingredient and packaging prices can move margins.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter cardiac drug, bank software and namkeen stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Cardiac_Drug_Bank_Software_and_Namkeen_Stocks\"><\/span><strong>Final Thoughts on Cardiac Drug, Bank Software and Namkeen Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cardiac drug, bank software and namkeen stocks<\/strong> reward patient research into demand, execution and financial strength. Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International each have a clear plan to grow. Based on the 18 November 2026 close, Eris Lifesciences trades at Rs 1,337.1, Oracle Financial Services Software at Rs 9,694.5 and Bikaji Foods International at Rs 480.75. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these cardiac drug, bank software and namkeen stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track cardiac drug, bank software and namkeen stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_cardiac_drug_bank_software_and_namkeen_stocks\"><\/span><strong>What are cardiac drug, bank software and namkeen stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cardiac drug, bank software and namkeen stocks are listed companies that sell branded medicines for heart and diabetes care, build software that banks use for daily operations, and make bhujia, namkeen and sweets sold across India. Their earnings depend on medicine demand, bank technology budgets and snack demand. This list looks at three of them, Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_cardiac_drug_bank_software_and_namkeen_stocks_are_covered_in_this_list\"><\/span><strong>Which cardiac drug, bank software and namkeen stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Based on the 18 November 2026 close, Eris Lifesciences traded at Rs 1,337.1, Oracle Financial Services Software at Rs 9,694.5 and Bikaji Foods International at Rs 480.75. Their return on equity ranges from <strong>15.9% to 33.7%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 10.4% to 22.9%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_cardiac_drug_bank_software_and_namkeen_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do cardiac drug, bank software and namkeen stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Cardiac drug, bank software and namkeen stocks<\/strong> have a strong roadmap in India because steady demand for chronic care medicines, banks upgrading their systems and rising demand for packaged snacks keep widening the market for these companies. The main drivers are as follows. Branded medicines. Patients stay on long-term treatment. Banking software. Banks upgrade their core systems. Snacks. Households buy packaged namkeen. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Eris_Lifesciences_performed_financially\"><\/span><strong>How has Eris Lifesciences performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Oracle_Financial_Services_Software_performed_financially\"><\/span><strong>How has Oracle Financial Services Software performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%. The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P\/E of 25.2, above the industry P\/E of 17.9. Looking ahead, the company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Bikaji_Foods_International_performed_financially\"><\/span><strong>How has Bikaji Foods International performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%. Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 45.8, above the industry P\/E of 33.9. Looking ahead, the company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_cardiac_drug_bank_software_and_namkeen_stocks\"><\/span><strong>What risks should investors check before buying cardiac drug, bank software and namkeen stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying cardiac drug, bank software and namkeen stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_cardiac_drug_bank_software_and_namkeen_stocks_investment_advice\"><\/span><strong>Is this list of cardiac drug, bank software and namkeen stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are cardiac drug, bank software and namkeen stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cardiac drug, bank software and namkeen stocks are listed companies that sell branded medicines for heart and diabetes care, build software that banks use for daily operations, and make bhujia, namkeen and sweets sold across India. Their earnings depend on medicine demand, bank technology budgets and snack demand. This list looks at three of them, Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which cardiac drug, bank software and namkeen stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Based on the 18 November 2026 close, Eris Lifesciences traded at Rs 1,337.1, Oracle Financial Services Software at Rs 9,694.5 and Bikaji Foods International at Rs 480.75. Their return on equity ranges from 15.9% to 33.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.4% to 22.9%.\"}},{\"@type\":\"Question\",\"name\":\"Why do cardiac drug, bank software and namkeen stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cardiac drug, bank software and namkeen stocks have a strong roadmap in India because steady demand for chronic care medicines, banks upgrading their systems and rising demand for packaged snacks keep widening the market for these companies. The main drivers are as follows. Branded medicines. Patients stay on long-term treatment. Banking software. Banks upgrade their core systems. Snacks. Households buy packaged namkeen. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Eris Lifesciences performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.\"}},{\"@type\":\"Question\",\"name\":\"How has Oracle Financial Services Software performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%. The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P\/E of 25.2, above the industry P\/E of 17.9. Looking ahead, the company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.\"}},{\"@type\":\"Question\",\"name\":\"How has Bikaji Foods International performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%. Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 45.8, above the industry P\/E of 33.9. Looking ahead, the company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying cardiac drug, bank software and namkeen stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying cardiac drug, bank software and namkeen stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of cardiac drug, bank software and namkeen stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cardiac Drug, Bank Software and Namkeen Stocks with a strong future roadmap: Eris Lifesciences, Oracle Financial Services Software and Bikaji Foods International. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":355938,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[26550,26552,26553,3803,13939,23509,20591,26551,13903,15391],"class_list":["post-355941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-bank-software-and-namkeen-stocks","tag-bank-technology-and-snacks-shares","tag-banking-software-and-ethnic-snacks-stocks","tag-best-stocks","tag-bikaji-foods-international","tag-branded-medicines","tag-cardiac-drug","tag-chronic-care-medicines","tag-eris-lifesciences","tag-oracle-financial-services-software"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355938"],"rank_math_title":["Cardiac Drug, Core Banking Software and Namkeen Stocks"],"rank_math_description":["Compare 3 cardiac drug, bank software and namkeen stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 17 Nov 2026."],"rank_math_focus_keyword":["cardiac drug, bank software and namkeen stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-heart-care-medicines-brand-bank-technology-provider-and-namkeen-snacks-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355941"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355941\/revisions"}],"predecessor-version":[{"id":355942,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355941\/revisions\/355942"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355938"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}